110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study

B7-H4 is highly expressed in OC and EC. Mo-Rez (GSK5733584), a novel ADC consisting of a humanized IgG1 monoclonal anti-B7-H4 antibody conjugated to a cyclopropyl-modified topoisomerase 1 inhibitor (drug–antibody ratio: 6), showed promising activity in global PROC and advanced/recurrent EC populations in BEHOLD-1 (NCT06431594). Here, we report additional data from the BEHOLD-1 study of Mo-Rez monotherapy, including B7-H4 expression and Mo-Rez activity by prior treatment.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108157
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study

M.C. Kaisermann, S. Lheureux, P.L. Bedard, R. Miller et al.
ESMO Open
HER2/EGFR in Cancer Research
article

110RO Mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody–drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): Additional data from BEHOLD-1 study

M.C. Kaisermann, S. Lheureux, P.L. Bedard, R. Miller, M.C. Lim, V. Salutari, J I Lee, S.D. Shah, W.B. McKean, V. Moreno Garcia, V. Boni, M.V. Dongen, S. Zildjian, J-S. Frenel, J. Veneris, F.J. Gonzalez Carreras, A. Riccio, A. Oaknin, I.L. Ray-Coquard
article en

Abstract

B7-H4 is highly expressed in OC and EC. Mo-Rez (GSK5733584), a novel ADC consisting of a humanized IgG1 monoclonal anti-B7-H4 antibody conjugated to a cyclopropyl-modified topoisomerase 1 inhibitor (drug–antibody ratio: 6), showed promising activity in global PROC and advanced/recurrent EC populations in BEHOLD-1 (NCT06431594). Here, we report additional data from the BEHOLD-1 study of Mo-Rez monotherapy, including B7-H4 expression and Mo-Rez activity by prior treatment.

ESMO OpenVol. 11
Université Claude Bernard Lyon 1 (FR), St Bartholomew's Hospital (GB), University of Toronto (CA), Yonsei University (KR), Samsung Medical Center (KR), Agostino Gemelli University Polyclinic (IT), Princess Margaret Cancer Centre (CA), National Cancer Center (US), Quantitative BioSciences (US), Hospital Universitario Puerta de Hierro Majadahonda (ES), Centre Léon Bérard (FR), Institut de Cancérologie de l'Ouest (FR), Hospital Universitario Quirónsalud Madrid (ES), Oncode Institute (NL), GlaxoSmithKline (United States) (US), NSK (United Kingdom) (GB), Hospital Universitario Fundación Jiménez Díaz (ES), Center for Cancer Research (US), GlaxoSmithKline (Spain) (ES), TE Laboratories (Ireland) (IE), University College London (GB)
Good health and well-being
Openalex Percentile: Top 8%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.